Analysts Set Biogen Inc. (NASDAQ:BIIB) Price Target at $214.23

Biogen Inc. (NASDAQ:BIIB) has received an average recommendation of “Moderate Buy” from the twenty-nine brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $215.6154.

Several equities research analysts recently issued reports on BIIB shares. Argus raised shares of Biogen to a “hold” rating in a report on Thursday, April 9th. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 1st. TD Cowen lifted their target price on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Wedbush lifted their target price on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research note on Thursday, April 30th. Finally, Truist Financial cut their target price on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research report on Monday, April 13th.

Hedge Funds Weigh In On Biogen

Hedge funds have recently modified their holdings of the stock. Rothschild Investment LLC grew its position in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares in the last quarter. Meeder Advisory Services Inc. raised its holdings in shares of Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after acquiring an additional 57 shares in the last quarter. Kera Capital Partners Inc. raised its holdings in shares of Biogen by 3.5% during the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 58 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after acquiring an additional 65 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after buying an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Up 0.8%

Shares of BIIB stock opened at $192.95 on Wednesday. Biogen has a 12 month low of $121.05 and a 12 month high of $205.97. The stock has a market cap of $28.49 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.68 and a beta of 0.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The company has a 50 day simple moving average of $185.21 and a two-hundred day simple moving average of $179.33.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts expect that Biogen will post 14.21 earnings per share for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said its Phase 2 CELIA study of diranersen (BIIB080), a tau-targeting Alzheimer’s drug, showed robust reductions in tau pathology and signals of slowed cognitive decline, prompting the company to advance the program into late-stage development. Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and lifted its price target to $250, while Oppenheimer raised its target to $300 and Evercore initiated coverage with an Outperform rating, reinforcing optimism around Biogen’s valuation and pipeline. Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250 Oppenheimer raises Biogen price target to $300 from $275, maintains Outperform rating
• Positive Sentiment: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding commercial products SYFOVRE and EMPAVELI and potentially improving near-term growth prospects. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Some analysts remain cautious, saying mixed Alzheimer’s data and pipeline uncertainty still create a balanced risk/reward profile despite the recent rally. Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
• Negative Sentiment: The CELIA study missed its primary endpoint, and a law firm has already announced an investigation into possible securities-law issues tied to the stock’s move after the data release, which could add headline risk. Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny – Contact Levi & Korsinsky for Details

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.